AstraZeneca (AZN) started a collaboration with Nucs AI to develop artificial intelligence-driven response prediction models for an oncology treatment, Nucs AI said Friday.
The collaboration will focus on creating predictive tools for a prostate-specific membrane antigen-targeted radioconjugate used in metastatic prostate cancer cases, the company said.
The company will modify and verify an imaging biomarker product to match upcoming radioconjugate therapies, Nucs AI said.
Price: 185.24, Change: -0.09, Percent Change: -0.05
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments